Cross-Sector entity
Acoziborole is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. Drugs for Neglected Diseases initiative (DNDi) appears in 2 tracked Cross-Sector stories from March 16, 2026.
2 verified stories tracked
Last mentioned: Mar 16, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Acoziborole is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. Drugs for Neglected Diseases initiative (DNDi) appears in 2 tracked Cross-Sector stories from March 16, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Drugs for Neglected Diseases initiative (DNDi). Shared-story counts are live from our verified record — not editorial picks.
Rollout Milestone
Acoziborole enters the final stages of regulatory rollout for endemic regions.
Trial Results
Phase 2/3 clinical trial results for Acoziborole show high efficacy.
Fexinidazole Approval
First all-oral 10-day treatment for sleeping sickness is approved.
Research Begins
DNDi starts screening compounds for a single-dose HAT treatment.
NECT Launch
Nifurtimox-eflornithine combination therapy improves safety but requires complex intravenous administration.
Melarsoprol Introduced
Arsenic-based treatment becomes standard but carries a 5% mortality rate due to toxicity.
The introduction of acoziborole, the first single-dose oral treatment for Human African Trypanosomiasis (sleeping sickness), marks a pivotal shift in global health efforts. Developed through a non-profit partnership between DNDi and Sanofi, the drug offers a simplified path to disease elimination by 2030.
The introduction of Acoziborole, a single-dose oral medication, marks a pivotal shift in the global fight against Human African Trypanosomiasis. This breakthrough treatment simplifies complex therapeutic regimens, potentially enabling the total elimination of the disease by 2030.
